CN102281898B - Il-20拮抗剂在治疗类风湿性关节炎和骨质疏松症中的应用 - Google Patents

Il-20拮抗剂在治疗类风湿性关节炎和骨质疏松症中的应用 Download PDF

Info

Publication number
CN102281898B
CN102281898B CN200980140331.2A CN200980140331A CN102281898B CN 102281898 B CN102281898 B CN 102281898B CN 200980140331 A CN200980140331 A CN 200980140331A CN 102281898 B CN102281898 B CN 102281898B
Authority
CN
China
Prior art keywords
antibody
mab
osteoporosis
antibodies
antagonist
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CN200980140331.2A
Other languages
English (en)
Chinese (zh)
Other versions
CN102281898A (zh
Inventor
张明熙
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Yongfu Biotechnology Co Ltd
Original Assignee
National Cheng Kung University NCKU
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US12/246,715 external-priority patent/US7837994B2/en
Application filed by National Cheng Kung University NCKU filed Critical National Cheng Kung University NCKU
Publication of CN102281898A publication Critical patent/CN102281898A/zh
Application granted granted Critical
Publication of CN102281898B publication Critical patent/CN102281898B/zh
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/12—Drugs for genital or sexual disorders; Contraceptives for climacteric disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/26—Androgens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/30—Oestrogens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/32—Fusion polypeptide fusions with soluble part of a cell surface receptor, "decoy receptors"

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Immunology (AREA)
  • Endocrinology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Pain & Pain Management (AREA)
  • Reproductive Health (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
CN200980140331.2A 2008-10-07 2009-10-07 Il-20拮抗剂在治疗类风湿性关节炎和骨质疏松症中的应用 Expired - Fee Related CN102281898B (zh)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US12/246,715 US7837994B2 (en) 2008-10-07 2008-10-07 Use of anti-IL-20 antibody for treating osteoporosis
US12/246,715 2008-10-07
US23866109P 2009-08-31 2009-08-31
US61/238,661 2009-08-31
PCT/US2009/059865 WO2010042634A1 (en) 2008-10-07 2009-10-07 Use of il-20 antagonists for treating rheumatoid arthritis and osteoporosis

Publications (2)

Publication Number Publication Date
CN102281898A CN102281898A (zh) 2011-12-14
CN102281898B true CN102281898B (zh) 2015-06-03

Family

ID=42100943

Family Applications (1)

Application Number Title Priority Date Filing Date
CN200980140331.2A Expired - Fee Related CN102281898B (zh) 2008-10-07 2009-10-07 Il-20拮抗剂在治疗类风湿性关节炎和骨质疏松症中的应用

Country Status (7)

Country Link
EP (1) EP2340039B1 (https=)
JP (2) JP5860699B2 (https=)
KR (1) KR101691534B1 (https=)
CN (1) CN102281898B (https=)
CA (1) CA2739794A1 (https=)
DK (1) DK2340039T3 (https=)
WO (1) WO2010042634A1 (https=)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103052403B (zh) 2010-04-16 2014-10-22 成功大学 通过阻断il-20受体活性治疗与il-20受体介导的信号通路相关的病症
WO2014006230A1 (en) 2012-07-06 2014-01-09 Novo Nordisk A/S Il-20 epitopes and il-20 ligands
CA2878825A1 (en) * 2012-07-10 2014-01-16 The Uab Research Foundation Compositions and methods for modulation of il-20 family cytokine activity
US8603470B1 (en) * 2012-08-07 2013-12-10 National Cheng Kung University Use of IL-20 antagonists for treating liver diseases
US9376490B2 (en) * 2014-04-01 2016-06-28 National Cheng Kung University Treatment of inflammatory pain using IL-20 antagonists
CN107249630A (zh) * 2014-11-24 2017-10-13 国家健康与医学研究院 通过il‑20r的拮抗作用治疗慢性阻塞性肺疾病的急性加重
US9982043B2 (en) 2016-06-03 2018-05-29 National Cheng Kung University Use of IL-20 antagonists for treating pancreatic cancer
KR101796025B1 (ko) 2017-04-25 2017-11-10 가톨릭대학교 산학협력단 사포그릴레이트, 프라바스타틴 및 tnf-억제제를 유효성분으로 포함하는 죽상동맥경화증 예방 또는 치료용 약학조성물

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX336813B (es) * 1996-02-09 2016-02-02 Abbvie Biotechnology Ltd Anticuerpos humanos que ligan el tnfa humano.
US6649779B2 (en) * 1997-05-02 2003-11-18 Wyeth Estrenes
IL136076A0 (en) * 1997-11-26 2001-05-20 Zymogenetics Inc Mammalian cytokin-like polypeptide -10
US20030148955A1 (en) * 1999-04-19 2003-08-07 Pluenneke John D. Soluble tumor necrosis factor receptor treatment of medical disorders
EP1244708B8 (en) * 1999-12-23 2007-03-07 ZymoGenetics, Inc. Method for treating inflammation
US7122632B2 (en) * 1999-12-23 2006-10-17 Zymogenetics, Inc. Soluble Interleukin-20 receptor
US6610286B2 (en) * 1999-12-23 2003-08-26 Zymogenetics, Inc. Method for treating inflammation using soluble receptors to interleukin-20
AU783473B2 (en) * 1999-12-23 2005-10-27 Zymogenetics Inc. Soluble interleukin-20 receptor
US20050143333A1 (en) * 2001-05-18 2005-06-30 Sirna Therapeutics, Inc. RNA interference mediated inhibition of interleukin and interleukin receptor gene expression using short interfering nucleic acid (SINA)
EP1429779A2 (en) * 2001-09-21 2004-06-23 Merck & Co., Inc. Androstanes as androgen receptor modulators
US20040235728A1 (en) * 2001-11-08 2004-11-25 Stoch Selwyn Aubrey Compositions and methods for treating osteoporosis
US7435800B2 (en) * 2003-05-23 2008-10-14 Chi-Mei Medical Center Antibodies to interleukin-20 and method for inhibiting interleukin-20 induced cell proliferation
WO2005052001A2 (en) * 2003-11-21 2005-06-09 Zymogenetics, Inc. Anti-il-20 receptor antibodies and binding partners and methods of using in inflammation
KR101351165B1 (ko) * 2006-03-30 2014-01-14 도레이 카부시키가이샤 수지상 폴리에스테르, 그의 제조 방법 및 열가소성 수지 조성물
JP5330829B2 (ja) * 2006-08-04 2013-10-30 憲弘 西本 関節リウマチ患者の治療予後予測方法

Also Published As

Publication number Publication date
JP2012505227A (ja) 2012-03-01
JP2016041730A (ja) 2016-03-31
EP2340039A1 (en) 2011-07-06
EP2340039B1 (en) 2015-11-25
CN102281898A (zh) 2011-12-14
KR20110094272A (ko) 2011-08-23
JP5860699B2 (ja) 2016-02-16
AU2009302383B2 (en) 2016-05-12
DK2340039T3 (en) 2016-02-29
CA2739794A1 (en) 2010-04-15
EP2340039A4 (en) 2012-10-24
WO2010042634A1 (en) 2010-04-15
AU2009302383A1 (en) 2010-04-15
KR101691534B1 (ko) 2017-01-09

Similar Documents

Publication Publication Date Title
US8454956B2 (en) Methods for treating rheumatoid arthritis and osteoporosis with anti-IL-20 antibodies
CN102281898B (zh) Il-20拮抗剂在治疗类风湿性关节炎和骨质疏松症中的应用
JP2020007354A (ja) 抗血漿カリクレイン抗体
US9365652B2 (en) Use of IL-20 antagonists for treating liver diseases
US9982043B2 (en) Use of IL-20 antagonists for treating pancreatic cancer
US20140065144A1 (en) Use of il-20 antagonists for promoting bone fracture healing
US9751949B2 (en) Method of inhibiting adipogenesis with an IL-20 antibody
US12409208B2 (en) Treating tissue fibrosis with interleukin 24
AU2013203707B2 (en) Use of il-20 antagonists for treating rheumatoid arthritis and osteoporosis
WO2014015133A1 (en) Treatment of osteoarthritis using il-20 antagonists
AU2009302383B9 (en) Use of IL-20 antagonists for treating rheumatoid arthritis and osteoporosis
US9512218B2 (en) Use of IL-20 antagonists for alleviating spinal cord injury
TW201210613A (en) Use of IL-20 antagonists for preventing rheumatoid arthritis and osteoporosis
US20170348389A1 (en) Treating liver diseases with interleukin 24

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C14 Grant of patent or utility model
GR01 Patent grant
TR01 Transfer of patent right

Effective date of registration: 20200306

Address after: Tainan City, Taiwan, China

Patentee after: Yongfu Biotechnology Co., Ltd

Address before: Tainan City, Taiwan, China

Patentee before: NATIONAL CHENG KUNG University

TR01 Transfer of patent right
CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20150603

Termination date: 20201007

CF01 Termination of patent right due to non-payment of annual fee